Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers

  • First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvantgiredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer
  • New data from the phase III IMpower010 study provide further insights into the role of Tecentriq® (atezolizumab) in early-stage non-small cell lung cancer (NSCLC)
  • Genomic data from the phase II CUPISCO study in Cancer of Unknown Primary (CUP), an uncommon type of cancer with high unmet need, could support diagnostics and more personalised treatment plans

Basel, 07 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new oncology data will be presented at the European Society for Medical Oncology (ESMO) Congress, which will be held 16-21 September, 2021. With one of the broadest oncology pipelines and portfolios in the industry, Roche presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung cancer, and a presentation on cancer of unknown primary (CUP), which has been selected for inclusion in the ESMO Press Programme.

“Our data at ESMO 2021 show how we continue to pursue potentially transformative advances in breast and lung cancer, particularly in earlier stage settings where the chance for cure is highest,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Furthermore our efforts in personalised healthcare, exemplified by our insights in CUP, will help address the needs of many patients who are diagnosed at a late stage.”

Breast Cancer Highlights
First phase II data will be presented from an interim analysis of giredestrant, a next-generation oral selective oestrogen receptor degrader (SERD), in neoadjuvant, ER-positive, HER2-negative early breast cancer. Over 70% of breast cancer cases are hormone receptor (HR)-positive, and there is a need for more effective and tolerable treatments, since up to 30% of patients develop resistance to standard of care treatments and in the adjuvant setting half of patients stop treatment due to the toll of side effects. Our efforts in this area represent a step towards making the treatment of patients with HR-positive breast cancer more effective and less debilitating in order to reduce the burden of treatment. This study further showcases Roche’s commitment to identifying meaningful treatment options for patients with breast cancer through a comprehensive development programme that includes early and late-stage HR-positive, HER2 positive and triple-negative forms of the disease.

Lung Cancer Highlights
New results from the phase III IMpower010 study, to be presented during Presidential Symposium Three, highlight patterns of relapse and subsequent therapy following treatment with Tecentriq® (atezolizumab) versus standard of care in early lung cancer, and help to define how Tecentriq fits into the adjuvant treatment pathway. These findings are particularly important as real-world data, which will also be presented at ESMO, will provide detail on the proportion of people with early NSCLC in the United States who do not receive adjuvant treatment despite guidelines recommending that they do so. These real world data also highlight survival outcomes in this setting and reinforce the need for more effective adjuvant therapy in NSCLC, as half of all people with early-stage lung cancer today still experience disease recurrence following surgery.

The phase III IMpower010 study showed adjuvant Tecentriq improved disease-free survival in PD-L1-positive early-stage lung cancer, compared with best supportive care - a first in cancer immunotherapy. Based on the outcomes from this study, the United States Food and Drug Administration recently granted Priority Review under the Real-Time Oncology Review pilot programme to Tecentriq as an adjuvant treatment for certain people with early NSCLC, and is expected to make a decision later this year.

Innovation in Personalised Healthcare
Latest results from a preliminary descriptive molecular analysis based on the CUPISCO study, which will be featured in the ESMO Press Programme, shed further light on the genomic profiles of patients with poor-prognosis CUP. These results highlight the importance of comprehensive genomic profiling for patients with CUP and identify therapeutically relevant genomic alterations in a significant proportion of patients, which may help to inform a more personalised treatment plan. In CUP, doctors cannot identify the location of the original (primary) tumour and can only find metastases. This causes practical problems since traditional treatment approaches rely on the site of origin being known, and as such, most patients are treated with nonspecific chemotherapy. Unfortunately, prognosis remains poor and the median survival following diagnosis is just six to 12 months, reinforcing the need for improved diagnosis and treatment.

Real world data from the United States examining the use of Foundation Medicine’s comprehensive genomic testing prior to first-line therapy in patients with metastatic colorectal cancer (mCRC) will also be presented and underpin Roche’s efforts to drive more widespread and earlier testing for patients with cancer.

Ahead of ESMO, Roche will also be hosting a virtual Personalised Healthcare in Oncology Symposium for healthcare professionals on Thursday 9 September, 13:00 – 14:30 CEST. In this symposium, different healthcare system experts from across the world will discuss how new and emerging solutions in personalised healthcare can help to improve patient outcomes, and ultimately their quality of life.

LinkedIn Live event - COVID-19 and Cancer: Reshaping Patient Care in the Context of the Pandemic Today and Tomorrow
Roche will also be hosting a live roundtable discussion on Wednesday 15 September 2021, 16:00 CEST that will focus on the global efforts to overcome the impact of the COVID-19 pandemic on cancer outcomes. The discussion, featuring experts from medical societies, academia and patient groups, will focus on what lessons have been learned so far, and how stakeholders can forge new paths and partnerships to find and deliver solutions for patients and society. Join this event on Roche’s LinkedIn page here.

Roche Oncology Newsroom
Roche’s ESMO Oncology Newsroom will be available from Tuesday 7 September for journalists to access exclusive materials sharing insights into Roche’s latest data, vision and strategy to pursue and advance scientific progress in order to improve the lives of people living with cancer. To access the newsroom, please register here.

Keep up to date with ESMO news and updates by using the hashtag #ESMO21 and follow Roche on Twitter via @Roche and LinkedIn.

Overview of key presentations featuring Roche medicines

MedicineAbstract titleAbstract or presentation number
Breast cancer
Giredestrant Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase 2 coopERA BC study LBA14
Kadcyla Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase 3 EMILIA study 284P
Kadcyla Trial in progress - ASTEFANIA: A phase 3 study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy 202TiP
Kadcyla Trial in progress - KATE3: A phase 3 study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer 329TiP
Real world data Real-world Outcomes of Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) metastatic Breast Cancer (mBC) with High Tumor Mutational Burden (hTMB) Treated with Immune Checkpoint Inhibitors (ICI) 237P
Lung cancer
Tecentriq IMpower010: Patterns of relapse and subsequent therapy from a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in stage IB-IIIA non-small cell lung cancer (NSCLC) LBA9
Tiragolumab Trial in progress - SKYSCRAPER-03: Phase III, Open-Label Randomised Study of Atezolizumab + Tiragolumab vs Durvalumab in Patients with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed After Platinum-based Concurrent Chemoradiation (cCRT) 1190TiP
Atezolizumab Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first line (1L) advanced/metastatic (m)NSCLC: results of the Blood First Assay Screening Trial (BFAST) Phase 3 Cohort C 1281O
Real world data Real-world Adjuvant Treatment Patterns and Survival Outcomes among early NSCLC US Patients 1158P
Real world data Adoption and early clinical outcomes of atezolizumab (atezo) + carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting 1650P
Bladder cancer
Atezolizumab Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC) 658MO
Gastric cancer
Atezolizumab Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-Gastric Cancer 1382P
Head and neck cancer
Tiragolumab Trial in progress - SKYSCRAPER-09: A Phase II, Randomised, Double-blinded Study of Atezolizumab (Atezo) + Tiragolumab (Tira) and Atezo + Placebo as First-line (1L) Therapy for Recurrent/Metastatic (R/M) PD-L1+ Squamous Cell Carcinoma of the Head and Neck (SCCHN) 927TiP
Hepatocellular carcinoma
Atezolizumab IMbrave150: exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) + bevacizumab (bev) or sorafenib (sor) 932P
Tumour agnostic treatment and personalised healthcare
Comprehensive genomic profiling Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO 1804P
Comprehensive genomic profiling Fusion and rearrangement (RE) detection using DNA and RNA-based comprehensive genomic profiling (CGP) of sarcomas 1532P
Comprehensive genomic profiling Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations 457P
Tumour agnostic Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN 80P
Real world data Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and Treatment Patterns in the real-world (RW) setting 1301P
Real world data Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) 477P

About Roche in Oncology
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa®(alectinib); Avastin®(bevacizumab); Cotellic®(cobimetinib); Erivedge®(vismodegib); Gavreto®(pralsetinib); Gazyva®/Gazyvaro®(obinutuzumab); Herceptin®(trastuzumab); Kadcyla®(trastuzumab emtansine); MabThera®/Rituxan®(rituximab); Perjeta®(pertuzumab); Polivy®(polatuzumab vedotin); Tarceva®(erlotinib); Rozlytrek®(entrectinib); Tecentriq®(atezolizumab); Venclexta®/Venclyxto®(venetoclax) in collaboration with AbbVie; Xeloda®(capecitabine); Zelboraf®(vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail:

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Patrick Barth
Phone: +41 61 688 44 86

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Karsten Kleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
Jon Kaspar Bayard
Phone: +41 61 68-83894

Dr. Sabine Borngräber
Phone: +41 61 68-88027
Dr. Bruno Eschli
Phone: +41 61 68-75284

Dr. Birgit Masjost
Phone: +41 61 68-84814
Dr. Gerard Tobin
Phone: +41 61 68-72942
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Gordon Brothers Names Karl Werner President, International Commercial & Industrial21.9.2021 15:00:00 CEST | Press release

Boston, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Gordon Brothers, the global advisory, restructuring and investment firm, has named Karl Werner President, International Commercial & Industrial. Werner, a former Ritchie Bros. executive, will join the senior leadership team to further develop and execute investment and disposition strategies across the firm’s International Commercial & Industrial practice. He and his team will partner with companies, their investors, lenders and advisors to overcome operational challenges, transform their businesses and dispose of assets. Werner comes to Gordon Brothers with an impressive 30-year track record in global asset management and disposition. He demonstrates innovative leadership in the commercial, industrial and auction industries where his teams have generated more than $1 billion in annual sales. “We are delighted to welcome Karl to Gordon Brothers,” said Frank Morton, CEO of International for Gordon Brothers. “He is a talented and consummate lead

Novozymes is combining cutting-edge science and business expertise to help feed the world sustainably21.9.2021 12:17:09 CEST | Press release

To feed a growing population, Novozymes is inviting all interested parties to help co-create and innovate the future of sustainable protein. By combining science with business expertise Novozymes wants to rethink how protein is made and sourced by enabling a new and progressive industry to provide sustainable nutrition. COPENHAGEN, DENMARK – 21 September, 2021 – As the U.N. Food System Summit sets the stage to bring about tangible, positive changes to the world’s food systems, Novozymes, the world leader in biological solutions, wants to rethink the way we manufacture and source protein. Novozymes announces the launch of the Myco-protein Innovation Call – a global platform to cultivate new business collaborations to scale up the most promising innovations and ideas around how to use fungi as a source of protein. “Realizing the importance of rethinking how we expand the adoption of plant-based protein and how we meet an increasing demand for sustainable nutrition, Novozymes is launching

Biotalys to Participate in Upcoming Investor and Stakeholder Events21.9.2021 12:00:00 CEST | Press release

Ghent, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Press release Biotalysto Participate in Upcoming Investor and Stakeholder Events Ghent, BELGIUM – 21September2021– Biotalys (Euronext - BTLS), an AgTech company focused on addressing food protection challenges to enable a more sustainable and safer food supply, today announces that it will be presenting at the following events during the remainder of 2021: Bryan-Garnier Food Tech Virtual Conference, 23-24 September CEO Patrice Sellès and CFO Wim Ottevaere will be speaking at Bryan Garnier & Co.’s Food Tech Conference on Friday 24 September at 15:00 CEST to an international audience of investors, with a presentation and Q&A session. Knowledge for Growth (FlandersBio), 28 September Biotalys will give a company presentation and participate in a panel debate on Europe’s Farm to Fork strategy at Knowledge for Growth on Tuesday 28 September 2021, at 14:00 CEST. The conference takes place in Ghent and is attended by decision makers from the biotech, p

TGS Share Repurchase21.9.2021 11:11:02 CEST | Press release

Oslo, Norway (21 September 2021) – On period from 16 September 2021 to 20 September 2021, TGS ASA (TGS) purchased 60,000 own shares on the Oslo Stock Exchange at an average price of NOK 83.8969 per share. Following the purchase TGS 1,076,095 own shares, representing 0.917% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)16-Sep-2120,00087.38141,747,62817-Sep-2120,00083.70701,674,14020-Sep-2120,00080.60241,612,048Previously disclosed buy-backs under the program (accumulated)950,995109.5342104,166,514Accumulated under the buy-back program1,010,995108.0127109,200,330The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 1,076,095 own shares, corresponding to 0.917% of TGS' share capital.Appendix:An overview of all


RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-09-21Loan2505 Coupon1.00 %ISIN-codeSE0011414010Maturity2025-05-12 Tendered volume, SEK mln1,250 +/- 650 Volume offered, SEK mln3,236Volume bought, SEK mln1,250 Number of bids7 Number of accepted bids3 Average yield0.194 %Lowest accepted yield0.190 %Highest yield0.197 %% accepted at lowest yield 83.33 Auction date2021-09-21Loan2611 Coupon1.00 %ISIN-codeSE0012569572Maturity2026-11-12 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,280 Volume bought, SEK mln1,250 Number of bids9Number of accepted bids6 Average yield0.417 %Lowest accepted yield0.415 %Highest yield0.424 %% accepted at lowest yield 77.00 Auction date2021-09-21Loan2805 Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1.250Volume bought, SEK mln500 Number of bids3 Number of accepted bids1 Average yield0.608 %Lowest accepted yield0.608 %Highest yield0.608 %% accepted at lowest yie

Mangold Insight presenterar ny analys om Terranets möjligheter21.9.2021 10:14:59 CEST | Pressemelding

I en ny analys upprepar Mangold Insight sin köprekommendation för Terranets aktie efter de senaste framstegen för företaget och med utgångspunkt i den höga aktiviteten i fordonsindustrin. Det expanderande teamet med ett högre kommersiellt fokus lyfts fram i kombination med den patenterade teknologin. Den livräddande VoxelFlow-tekniken kompletterar annan sensorteknologi i dagens fordon. Möjligheten att kunna klassificera och följa objekt upp till hundra gånger snabbare än branschstandarden är dess mest unika attribut, i kombination med den höga bildkvaliteten som teknologin genererar. Du hittar analysen "Snabbare Takt framåt" här: För mer information om Terranet: Pär-Olof Johannesson Tel: +46 70 332 32 62 E-post: Om Terranet Terranet (Nasdaq: TERRNT-B.ST). Med visionen att rädda liv utvecklar Terranet sensorteknologi för kollisionsvarning i trafiken. Bolaget levererar mjukvara med tillämningar för avancerat förarstöd och autonoma fo